Optimizing therapy of chronic myeloid leukemia

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Chronic myeloid leukemia (CML) is driven by the Bcr-Abl tyrosine kinase, a product of the Philadelphia chromosome.
• Imatinib is the standard therapy for CML, significantly reducing the need for stem cell transplantation.
• Despite high response rates, imatinib does not eliminate all leukemic stem cells, leading to persistent residual disease.

Purpose of the Study:

• To review current perspectives on imatinib therapy for CML.
• To discuss factors influencing treatment outcomes and reasons for therapeutic failure.
• To explore strategies for achieving complete disease elimination and managing imatinib resistance.

Main Methods:

• Review of current literature on imatinib therapy in CML.
• Analysis of data from standard and high-dose imatinib treatment regimens.
• Discussion of prognostic factors and mechanisms of resistance.

Main Results:

• Imatinib achieves high rates of cytogenetic response but rarely eradicates CML completely.
• Residual leukemic stem cells persist in most patients treated with imatinib.
• Mechanisms of imatinib failure and resistance are complex and multifactorial.

Conclusions:

• Complete eradication of CML may require novel therapeutic strategies beyond imatinib.
• Monitoring prognostic factors is crucial for optimizing CML treatment.
• Second-generation tyrosine kinase inhibitors offer potential for overcoming imatinib resistance.